Abstract. B-precursor acute lymphoblastic leukemia (B-ALL) is the most common cancer diagnosed in children and adolescents. Despite the fact that the 5-year survival rate has increased from 60 to 90%, approximately a quarter of children suffer from relapse with poor outcome. To improve the clinical management of B-ALL, there is an urgent need for prognostic biomarkers for the prediction of B-ALL outcomes. In the present study, we performed a comprehensive analysis of the gene expression data of 456 samples from five independent cohorts. We first sought to identify B-ALL-associated genes by differential gene expression analysis by applying linear models. Then, the statistical modelling was applied to identify candidates related to relapse-free survival. We identified a total of 1,273 B-ALL-associated genes that have functions relevant to chemokine signaling. From these genes, 59 genes were identified as prognostic biomarkers. Based on expression patterns of these genes, we successfully distinguished high-and low-risk groups of B-ALL patients (log-rank test, P-value=0.025). We further investigated the 59-gene expression levels in ALL chemotherapy-treated cohorts and identified 4 genes as potential drug targets associated with drug sensitivity. Our results provided a novel biomarker panel. By leveraging the large scale of data and statistical modelling, we believe this 59-gene biomarker could help to unveil the mechanisms underlying B-ALL progression and become potential drug targets.
Introduction
B-precursor acute lymphoblastic leukemia (B-ALL) is the most common cancer diagnosed in children and adolescents (1, 2) . One of the major causes of mortality is relapse despite intensive multi-agent chemotherapy (3) . For the past two decades, several studies have reported that molecular abnormalities including TP53 mutations (4), deletion of INK4A/ARF (5) and TEL deletion (6) contribute to B-ALL relapse. However, the pathogenesis and biological mechanisms underlying relapsed ALL remain largely unknown. Thus, we sought to provide novel insights by identifying prognostic biomarkers from genome-wide expression profiling data generated by DNA microarrays.
Microarray technology has been developed more than a decade ago and is widely used in biomedical and clinical research. This high-throughput strategy enables profiling genome-wide expression simultaneously. Previously, based on committee neural networks, the leukemia gene expression data can be subcategorized into B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia and acute myeloid leukemia (7) . Unsupervised hierarchal clustering of ALL gene expression could be used to reveal unique clusters with distinct cytogenetic, genomic and transcriptomic characterizations (8) . By comparing gene expression profiles of specimens at the time of diagnosis vs. at relapse, or early-vs. late-relapse, several biological pathways such as cell cycle regulation, WNT and mitogen-activated protein kinase pathways (9, 10) were identified to contribute to ALL relapse.
However, these findings lack connections to clinical practice, as the prediction of prognosis plays a crucial role in facilitating clinical decision-making. The purpose of this study was to develop a prognostic biomarker from gene expression profiles. Unlike the previously published study (11), we integrated data sets from multiple cohorts and implemented a comprehensive computational pipeline to identify a 59-gene biomarker that could serve as a B-ALL prognostic biomarker in practical applications.
Materials and methods
Gene expression data and preprocessing. We collected raw microarray data from two cohorts including TARGET-ALL study (11) and Microarray Innovations in LEukemia (MILE) (12, 13) . For the TAGET-ALL study, 207 high-risk B-precursor ALL patients between March 15, 2000 and April 25, 2003 were recruited from the Children's Oncology Group (COG) Clinical Trial P9906. RNA was first purified from samples with >80% blasts (131 bone marrow, 76 peripheral blood) and then hybridized to Affymetrix Human Genome U133 Plus 2.0 Array. The raw intensity *.CEL files were retrieved from NCBI Gene Expression Omnibus (http://www. ncbi.nih.gov/geo) under the accession number GSE11877. For the MILE study, there were in total 2,096 blood or bone marrow samples of acute and chronic leukemia patients from 11 participant centers. In this study, we restricted to take 74 non-leukemia healthy samples as controls. Consistent with the TARGET-ALL study, Affymetrix Human Genome U133 Plus 2.0 Array was also used for the gene expression profiling.
For the discovery of prognostic biomarkers, we used the gene expression data set from one previously published study (14) , where 80 samples collected at the time of diagnosis were considered in this study. The RNA was hybridized to Affymetrix HG-U133A oligonucleotide microarrays. The raw intensity *CEL files were retrieved from EBI ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) under the accession number E-MTAB-1216.
The raw intensity *.CEL files were preprocessed using the frma (15) package in R 3.4.1 (https://www.r-project.org) environment. Briefly, the frma package converted raw probe-level intensities into background-corrected gene-level intensities. The data was then normalized based on the estimation of probe-specific effects, which allowed us to combine data from various cohorts without batch effects.
Identification of B-ALL-associated genes.
We sought to identify B-ALL-associated genes by performing differential gene expression analysis between B-ALL (n=207) and healthy samples (n=74). The R package limma (16) package was used to conduct the differential gene expression analysis. The expression data was first Log2 transformed and then fitted into linear models with Empirical Bayesian methods for the analysis. We filtered the results at Log2 fold-change ≥2, or ≤-2 and B-statistics ≥4.6, which indicates that the probabilities of the genes were differentially expressed were >99%. After filtering, 1,273 genes were identified. The gene set enrichment analysis was then conducted using the R package clusterProfiler (17) . The enrichment P-value was Benjamini & Hochberg adjusted.
Prognostic biomarker identification for relapse-free survival (RFS).
For the development of prognostic gene signature, the 1,273 B-ALL-associated genes were first fitted with the Cox proportional hazards model in 80 samples. The prognostic significance of each gene test was assessed by log-rank test. We selected 59 at the cut-off P-value ≤0.05. The hierarchal clustering algorithm was then applied to the 59-gene expression profiles and the patients were divided into high-and low-risk groups. The Kaplan Meier-plot and log-rank test were used to test the prognostic significance of the two groups. 
Results
In the present study, we sought to identify B-ALL RFS biomarkers using transcriptome data. We hypothesized that the biomarkers may be involved in B-ALL pathogenesis, thus the gene differential expression analysis was conducted by comparing 207 B-ALL samples with 74 healthy normal blood, or bone marrow samples. After applying the linear models and stringent cut-off [Log fold-change ≥2, ≤-2, and false discovery rate (FDR) ≤0.01], a total of 1,273 genes were identified as ALL-associated genes as they were significantly upregulated or downregulated in the ALL samples (Fig. 1) .
The Gene Ontology (GO) enrichment analysis revealed that the B-ALL-associated genes were involved in various biological processes (Table I) . Surprisingly, we found that the B-ALL-associated genes were most significantly enriched in the biological processes that respond to bacterium (GO:0009617). We further categorized these genes and found that they were involved in cytokine-cytokine receptor interaction pathway (Fig. 2) . These genes include chemokine ligands (CCL5, CXCL1, CXCL16, CXCL2, CXCL3, CXCL8), tumor and the CXCR4-CXCL12 axis (23) that have been identified as potential targets in leukemia treatment. Then, we applied Cox proportional hazards modelling to the B-ALL-associated genes and selected 59 top ranked genes based on log-rank test P-values as B-ALL RFS genes (Table II) . After applying the hierarchal clustering to this 59-gene profile, the high-(n=20), and low-risk (n=60) samples were identified from the B-ALL cohort with significant (log-rank test P=0.025) different relapse-free survival outcome (Fig. 3) . The B-ALL RFS biomarkers included genes from various families, such as glycosyltransferases (C1GALT1 and B4GALT5), RAS oncogene GTPases (RAB27B and RAB7A), nuclear hormone receptors (NR3C1 and RORA), RNA binding proteins (RBM6 and U2SURP) and Zinc finger proteins (PLAGL2, SP1 and ZNF91). We also found that among these biomarkers, 4 genes, B4GALT5, CDK6, PDZD8 and RAB7A, were candidates that were associated with chemotherapy response (Fig. 4) in two independent ALL cohorts, GSE19143 (n=52) (24) and GSE13280 (n=44) (25) where patients were treated with prednisolone. Indeed, the B4GALT family is involved in mediating drug resistance in human leukemia cells by regulating the Hedgehog pathway (26) . This suggest that the 59-gene biomarker could also indicate drug sensitivity in ALL treatment.
Discussion
The major challenge in clinical treatments of B-precursor acute lymphoblastic leukemia (B-ALL) is relapse after chemotherapy; thus or the development of alternative treatments is critical. Here, we demonstrated the ability of gene expression profiling to reveal not only biological mechanisms but also clinical diagnostic markers.
Among the 59 genes, several genes have been characterized as being involved in the progression of leukemia and solid tumors. For instance, MME, which is also known as CD10, or CALLA, encodes a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen. It is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (27) has been well-documented in many leukemia-related studies (28) (29) (30) (31) (32) . SOCS3 is a member of the suppressor of cytokine signaling (SOCS) family and negatively regulates JAK2 kinase. Its altered expression is associated with leukemia (33, 34) and solid tumors including melanoma (35) (36) (37) (38) , cervical cancer (39) (40) (41) , renal cell carcinoma (42) (43) (44) (45) , prostate cancer (46, 47) and gastric cancer (48) . CDK6 is a serine/threonine protein that is important for cell cycle G 1 phase progression and G1/S transition. CDK6 is dysregulated or disrupted in many types of cancer (49) (50) (51) (52) (53) (54) , and it is previously Fifty-nine genes associated with B-ALL relapse-free survival. HR, hazard ratio; CI, confidence interval; B-ALL, B-precursor acute lymphoblastic leukemia; RFS, recurrence-free survival.
reported to be in a three-way rearrangement including other two elements: MLL and AF-4 in a case of infant ALL (55) . This indicates the biological relevance of the 59-gene biomarker to B-ALL and could propose new directions for investigations. However, we do realize that there is merely a one gene (JCHAIN known as IGJ) overlap of our 59-gene biomarker with a previously published 38-gene classifier (11) . We reasoned that this discordance is due to differences in the analysis strategy. While in the previous study, the biomarker selection was implemented directly on all of the microarray probe sets, we pre-filtered the candidate list to B-ALL-associated genes by differential gene expression analysis. We also optimized the process of preprocessing the microarray data by using up-to-date algorithms and software, which could lead to higher confidence in producing final results.
In conclusion, our systematic approach provided an intriguing guideline for the identification of B-ALL prognostic biomarkers and revealed their potential roles in chemosensitivity. Further investigations are expected to validate the performances of these biomarkers before being applied to clinical management. As the RNA-seq technologies are trending in transcriptome profiling, we will also collect RNA-seq data to re-train and optimize our model. We will also try to reduce the number of biomarkers while maintaining the predictive power, so that the application in clinical management is more feasible. .05, *** 0.0001<P<0.01). P-values were computed using Wilcoxon rank sum and signed tests.
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